Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	At The Market Offering	Common Stock	Common Stock At The Market Offering	Additional Paid-in Capital	Additional Paid-in Capital At The Market Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2023	$ 287,506		$ 20		$ 1,625,637		$ (60)	$ (1,338,091)
Beginning balance (in shares) at Dec. 31, 2023			197,857
Issuance of common stock, net of offering costs (in shares)			21,773	150
Issuance of common stock, net of offering costs	180,008	$ 1,037	$ 2		180,006	$ 1,037
Fees incurred related to common stock financings/issuance of common stock from at the market offering		$ (113)
Vesting of restricted stock (in shares)			386
Exercise of stock options	4,929				4,929
Exercise of stock options (in shares)			1,120
Stock-based compensation expense	9,092				9,092
Unrealized gain (loss) on marketable securities, net	45						45
Net income (loss)	(107,475)							(107,475)
Ending balance at Mar. 31, 2024	375,142		$ 22		1,820,701		(15)	(1,445,566)
Ending balance (in shares) at Mar. 31, 2024			221,286
Beginning balance at Dec. 31, 2024	$ 250,504		$ 22		1,855,318		14	(1,604,850)
Beginning balance (in shares) at Dec. 31, 2024	223,923		223,923
Fees incurred related to common stock financings/issuance of common stock from at the market offering	$ (171)				(171)
Vesting of restricted stock (in shares)			960
Exercise of stock options	$ 1,127		$ 1		1,126
Exercise of stock options (in shares)	523		580
Stock-based compensation expense	$ 7,022				7,022
Unrealized gain (loss) on marketable securities, net	(14)						$ (14)
Net income (loss)	(49,389)							(49,389)
Ending balance at Mar. 31, 2025	$ 209,079		$ 23		$ 1,863,295			$ (1,654,239)
Ending balance (in shares) at Mar. 31, 2025	225,463		225,463